500735-24-0Relevant articles and documents
Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: Orally active inhibitors of lck kinase
Goldberg, Daniel R.,Butz, Tanja,Cardozo, Mario G.,Eckner, Robert J.,Hammach, Abdelhakim,Huang, Jessica,Jakes, Scott,Kapadia, Suresh,Kashem, Mohammed,Lukas, Susan,Morwick, Tina M.,Panzenbeck, Maret,Patel, Usha,Pav, Susan,Peet, Gregory W.,Peterson, Jeffrey D.,Prokopowicz III, Anthony S.,Snow, Roger J.,Sellati, Rosemarie,Takahashi, Hidenori,Tan, Jonathan,Tschantz, Matt A.,Wang, Xiao-Jun,Wang, Yong,Wolak, John,Xiong, Pla,Moss, Neil
, p. 1337 - 1349 (2007/10/03)
The tyrosine kinase p56lck (lck) is essential for T cell activation; thus, inhibitors of lck have potential utility as autoimmune agents. Our initial disclosure of a new class of lck inhibitors based on the phenylaminoimidazoisoquinolin-9-one showed reaso
